ĒnelAtlasSearch the Atlas

The Compound Intelligence Library

Compounds

Investigational and established non-peptide compounds, separated from supplements and peptide drugs.

6 compounds, ordered below with the best evidenced first.

What the evidence looks like across all 6 compounds

More than half of this library rests on animal data or less. That is the finding, not a gap in the reading.

Number of compounds at each evidence grade.
Gradecompounds
5Settled0
4Strong0
3Mixed0
2Thin3
1Untested3

0 compounds rest on strong human evidence. 6 rest on little or none. How we grade evidence.

Browse by category

All Compounds6Investigational1Metabolic1

Amlexanox

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

Amlexanox (small-molecule TBK1/IKK-epsilon inhibitor; not a peptide)

Amlexanox is a small-molecule anti-inflammatory drug (not a peptide) that is FDA-approved as Aphthasol 5% oral paste for canker sores and marketed in Japan as Solfa for asthma and allergic rhinitis. The obesity and type 2 diabetes repurposing, based on its inhibition of the kinases TBK1 and IKK-epsilon in the Saltiel lab, reached only a single small phase 2 trial with modest, responder-dependent metabolic effects, which is the experimental use grouped with fat-loss peptides in community protocols.

Metabolic / CombinationFDA-approved as Aphthasol 5% oral paste for recurrent aphthous ulcers (1997), since discontinued in the US; metabolic/obesity use is investigational only

SANA/MVD1

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

5-(2-nitroethenyl)salicylic acid

One small first-in-human safety study reported exploratory metabolic signals. Human efficacy and long-term safety remain unestablished.

Investigational nitroalkene small moleculeThe reviewed primary publication and trial registry establish clinical-development status, not governmental marketing authorization. No approved medical use was established in this research pass.

Tesofensine

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

Triple Monoamine Reuptake Inhibitor

Not a peptide but a synthetic small-molecule triple monoamine reuptake inhibitor, frequently discussed alongside weight-loss peptides. It showed strong Phase 2 weight loss (TIPO-1) and completed a Phase 3 obesity program in Mexico, but it is not FDA or EMA approved and carries cardiovascular and psychiatric safety concerns.

Weight Loss / MonoamineNot FDA approved; investigational new drug in the United States, with Phase 3 obesity data generated in Mexico rather than the US

5-Amino-1MQ

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

NNMT Inhibitor Small Molecule

Not technically a peptide but grouped with them in the community, a small-molecule NNMT inhibitor that increases cellular NAD+ and may reduce fat-cell size in animal models. Rising fast in metabolic biohacking.

Metabolic / NNMT InhibitorNo FDA approval; investigational small molecule with only preclinical (animal and in-vitro) data; not on the FDA 503A compounding bulk list; sold gray-market for research use only.

Follistatin 344

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Myostatin Inhibitor Glycoprotein

A naturally produced protein that inhibits myostatin, the body's brake on muscle growth. Dramatically increases muscle mass in animal models; studied in muscular dystrophy.

Myostatin InhibitorNot approved. No FDA-approved follistatin product for any indication. Gene-therapy use exists only as investigational protocols (open-label Becker MD trial under IND) and as unapproved offshore commercial offerings; gray-market FST-344 is sold as a research chemical not for human consumption.